keloid; keloid/physiopathology; keloid/therapy; skin and connective tissue diseases; pathologic processes; fibrosis; pruritus; itching; phosphodiesterase 4 inhibitors; crisaborole


Dermatology | Pharmacy and Pharmaceutical Sciences | Skin and Connective Tissue Diseases



The pathophysiology of keloid formation is poorly understood, and current treatments, including intralesional corticosteroids, cryotherapy, and surgery, are often associated with high resistance to treatment and recurrence. The multifactorial pathogenesis of keloid formation suggests that aberrant inflammatory cytokine signaling associated with keratinocyte dysregulation may contribute to keloid-associated pruritus.

Case Presentation

In this paper, we report 2 cases of keloid-associated pruritus that were successfully treated with topical crisaborole 2% ointment, a phosphodiesterase 4 (PDE4) inhibitor. Both patients had previously undergone multiple unsuccessful treatments before being treated with crisaborole 2% ointment. In both cases, the patients experienced complete relief of pruritus with no significant change in keloid size, thickness, or appearance.


We propose that PDE4 inhibitors, such as crisaborole, may be an effective therapy for keloid-associated pruritus.